UnitedHealth Is Shrinking Its Scope — and That Is the Point

UnitedHealth Group, the world's largest health insurer, has sold an interest in its Florida WellMed clinics to the private-equity firm TPG. The transaction follows TPG's acquisition, earlier this year, of UnitedHealth's entire UK healthcare business — Optum UK — which closed in March.

The buyer is the same. The logic is the same. UnitedHealth is no longer trying to do everything itself.

It would be easy to treat these sales as small rearrangements inside a company with $447 billion in annual revenue. The more useful way to look at them is as a signal about what UnitedHealth now believes it can manage, and what it is prepared to hand off.

The collapse that preceded the retreat

UnitedHealth's 2025 was a reckoning. Revenue reached a record $447.6 billion — a 12% increase — but net profit fell to $12.1 billion from $14.4 billion, its lowest since 2018. The operating margin of the insurer arm, UnitedHealthcare, was halved from 5.2% to 2.7%. Earnings per share fell by roughly a third.

The damage came from four directions, none of them entirely outside the company's control. The Biden-era V28 coding overhaul — which regulators phased in over three years to curb inflated medical coding — cut payments to insurers and value-based care companies by an estimated $130 billion industry-wide. The Inflation Reduction Act's drug-price negotiations reduced rebate revenue through Optum Rx. The medical loss ratio climbed from 85.5% in 2024 to 89.1% in 2025, meaning a higher share of premium revenue went straight to paying for care. And lingering costs from the 2024 Change Healthcare cyberattack added a multi-billion-dollar headwind.

The most dramatic swing occurred in Optum Health, the value-based care division that runs physician practices including WellMed. It generated $7.8 billion in operating earnings in 2024. In 2025 it posted a loss of $278 million. That single unit alone accounted for the majority of UnitedHealth's overall profit decline.

Leadership turnover followed. CEO Andrew Witty stepped down in May 2025 and was replaced by Stephen Hemsley, the company's former CEO from 2006 to 2017. A new CFO, Wayne DeVeydt, was brought in from Elevance Health — UnitedHealth's chief domestic rival. The cast change was not decorative. It was a response to the worst year in the company's modern history.

What WellMed is and why Florida matters

WellMed is one of the largest Medicare-focused primary-care networks in the United States, with roughly 300 clinics across Texas and Florida. It is the clinical face of UnitedHealthcare's Medicare Advantage plans — the privately managed alternative to traditional Medicare. When a Medicare patient in Florida chooses a UnitedHealthcare Advantage plan, they are often directed to a WellMed clinic for their primary care.

That is an integrated model: the insurer (UnitedHealthcare) pays for care that its own clinic network (WellMed, via Optum Health) delivers. On paper, it is supposed to create alignment — the entity paying the bill also controls the cost. In practice, the integration makes UnitedHealth vulnerable to regulatory pressure from both sides. Insurers face rate reviews and coding audits; care providers face quality metrics and payment restrictions. UnitedHealth has been the biggest target of both, precisely because it is the biggest player on both sides.

Florida is the single most important Medicare market in the country. The state's rapidly aging population makes it a growth engine — and a battleground. UnitedHealth is still opening roughly 15 new clinics there each year. Selling an interest to TPG does not mean abandoning Florida. It means sharing the operational burden of running those clinics with a partner whose entire business model is focused on scaling healthcare assets.

Focus, not distress

Mr DeVeydt was explicit about the motivation. "We didn't need the dollars, we have the dollars to invest, but we needed the focus and somebody that could actually work with us locally." Optum Health's CEO, Krista Nelson, added that the partnership was brought in "so we could make some more investment in the market and be positioned for strategic growth."

These are not the words of a company raising emergency capital. They are the words of a company deciding what to stop doing, at least alone.

The same logic applies to the Optum UK sale. UnitedHealth paid roughly £1.2 billion ($1.6 billion at the time) in 2023 to acquire Optum UK and EMIS Group, a health-records software company. Less than three years later, it was offloaded to TPG for a similar valuation, with $400 million of the proceeds going to the United Health Foundation. A non-core international operation that complicated the balance sheet and the story has been removed.

The pattern is clear: UnitedHealth is shrinking its scope. Not out of financial weakness — it generated $11.1 billion in operating cash flow in the second quarter of 2026 and has repurchased at least $2 billion in stock since January. Out of strategic simplification.

The turnaround has already begun

The financial data from the first half of 2026 does not suggest a company still reeling. Operating margins recovered to 8% in the first quarter of 2026 — a dramatic improvement from less than 1% in the fourth quarter of 2025. Operating income rose from $380 million in that trough quarter to $8.99 billion. The second quarter maintained the momentum: earnings from operations reached $5.5 billion, with operating margins of 4.9% on $112 billion in revenue.

Management raised its full-year 2026 adjusted earnings-per-share guidance to a range of $19.50 to $20.00, well above the $17.75 floor it set at the beginning of the year. Optum Health is the unit investors care about most, since that was where the blood loss occurred. The CFO projects Optum Health margins improving from roughly 2% this year to around 4% in 2027 and 6% in 2028. An independent analyst at Leerink forecasts 3.8% in 2027 and 6.5% in 2028. Whether the company hits 6% or 6.5% is a detail; the agreement between management and analysts on the direction is the signal.

Membership contraction has been the medicine. UnitedHealthcare shed between 1.3 million and 1.4 million Medicare Advantage members in 2026 — a deliberate reduction designed to exit unprofitable markets and improve the quality of the remaining book. Revenue is expected to dip slightly, from $447.6 billion in 2025 to around $439 billion in 2026. The company is choosing a smaller, more profitable business over a larger, thinner one.

The stock reflects the recovery. UnitedHealth shares are up roughly 39% year-to-date in 2026, having rallied from a 2025 low of around $283. The current price sits near $400, implying a trailing P/E ratio in the mid-20s — close to where the stock traded before the 2025 deterioration. The market has accepted that the worst is over.

The question the margin numbers do not answer

The remaining uncertainty is structural, not cyclical. UnitedHealth built itself on a dual model — insuring and treating — that was powerful when the regulatory environment was permissive. The V28 coding overhaul, risk-score auditing, and Medicare Advantage rate pressures suggest that environment has shifted. The company can adapt, as it is now doing. But the integrated model that made UnitedHealth unique also makes it the most visible target for any administration that wants to constrain health-insurer profits.

Selling interests in WellMed clinics to a private-equity firm does not reduce UnitedHealth's regulatory exposure. It may actually increase complexity: UnitedHealth will still underwrite the insurance, set the benefit design, and pay the claims, while TPG co-owns the clinics that deliver the care. That is a partnership, not a separation. If the incentives between insurer and provider diverge — as they tend to — the coordination that made the original integrated model valuable will fray.

To be sure, this is a risk that applies to any health insurer with affiliated providers, not a unique flaw. UnitedHealth's scale and data infrastructure give it more leverage to manage the relationship than a smaller player would. And the CFO's framing — "we needed the focus" — is internally consistent. A simplified portfolio is easier to run, easier for investors to understand, and easier for regulators to evaluate.

The investment question is simpler than the structural one. The stock is being valued as though the turnaround is real and the margin recovery will persist. That is a fair assessment given the evidence so far. The price near $400 implies a forward earnings multiple of roughly 21 times the guidance midpoint of $19.50 to $20.00. That is not cheap for a $440-billion-revenue company — but it is not expensive either, for one that has already demonstrated its ability to fix a broken income statement.

The WellMed sale to TPG is not a headline event. It is a data point in a larger restructuring. It tells an investor that UnitedHealth's management now believes the best use of its capital is not in owning more clinics, but in running a leaner, more profitable business. Whether that belief proves right is a question the next few quarters of Optum Health margins will answer.